The landscape of mutations affecting ncRNA in PCNSL was comparable to ABC-DLBCL, apart from significantly more mutations in AL122127.1 and AL122127.4 (Fig. 3a), situated in the IGH locus, and in RP11-211G3.2, situated in the first intron of BCL6. While the implications of these mutations are unclear, it is possible that these mutations are accumulated as part of the SHM/aSHM process affecting IGH and BCL6. Additionally, we identified recurrent aberrations in the aSHM target MIR142 (80%; Fig. 3a, b) as well as MALAT1 (70%) and NEAT1 (60%), both located 53 kb apart on 11q13.1. This evidence concerns the gene BCL6 and primary central nervous system lymphoma.